Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Receives CE Mark for Overa

NEW YORK (GenomeWeb) – Vermillion said today that it has received a CE mark for its Overa ovarian cancer test, a second-generation version of its OVA1 test.

The company is now cleared to market Overa in the EU, and is "actively identifying global partnerships" to sell the test, Vermillion President and CEO Valerie Palmieri said in a statement.

Like OVA1, Overa is intended for triaging patients with ovarian adnexal masses as part of preoperative evaluations to determine the likelihood that a mass is cancerous.

According to Vermillion, Overa offers several improvements over the existing OVA1 test, including a 28 percent improvement in specificity, a 29 percent improvement in positive predictive value, and a 20 percent improvement in overall clinical accuracy.

The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.